Multiple Sclerosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019 SBWire (press release) Aubagio (teriflunamide), Dimethyl Fumarate (BG-12), Daclizumab, RG1594 (ocrelizumab) and Lamtrada (alemtuzumab) are the novel late stage pipeline products likely to enter the market through to 2019. |
